The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Open accessAbstract
Background Hydroxychloroquine or chloroquine with or without azithromycin have been widely promoted to treat coronavirus disease 2019 (COVID-19) following early in vitro antiviral effects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objective The aim of this systematic review and meta-analysis was to assess whether chloroquine or hydroxychloroquine with or without azithromycin decreased COVID-19 mortality compared with the standard of care. Data sources PubMed, Web of Science, Embase Cochrane Library, Google Scholar and MedRxiv were searched up to 25 July 2020. Study eligibility criteria We included published and unpublished studies comparing the mortality rate between patients treated with chloroquine or hydroxychloroquine with or without azithromycin and patients managed with standard of care. Participants Patients ≥18 years old with confirmed COVID-19. Interventions Chloroquine or hydroxychloroquine with or without azithromycin. Methods Effect sizes were pooled using a random-effects model. Multiple subgroup analyses were conducted to assess drug safety. Results The initial search yielded 839 articles, of which 29 met our inclusion criteria. All studies except one were conducted on hospitalized patients and evaluated the effects of hydroxychloroquine with or without azithromycin. Among the 29 articles, three were randomized controlled trials, one was a non-randomized trial and 25 were observational studies, including 11 with a critical risk of bias and 14 with a serious or moderate risk of bias. After excluding studies with critical risk of bias, the meta-analysis included 11 932 participants for the hydroxychloroquine group, 8081 for the hydroxychloroquine with azithromycin group and 12 930 for the control group. Hydroxychloroquine was not significantly associated with mortality: pooled relative risk (RR) 0.83 (95% CI 0.65–1.06, n = 17 studies) for all studies and RR = 1.09 (95% CI 0.97–1.24, n = 3 studies) for randomized controlled trials. Hydroxychloroquine with azithromycin was associated with an increased mortality (RR = 1.27; 95% CI 1.04–1.54, n = 7 studies). We found similar results with a Bayesian meta-analysis. Conclusion Hydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients but the combination of hydroxychloroquine and azithromycin significantly increased mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827
McGuinness, L. A., & Higgins, J. P. T. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1411 · Cited by 5,579 · cited 1×
“1 with meta package and robvis package [35].”
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481 · cited 2×
“Under the hypothesis of having a baseline mortality risk of 26% (based on ISARIC WHO CCP-UK cohort [29]), these pooled relative risk values would correspond to a non-significant risk difference of e4.”
Outlier and influence diagnostics for meta-analysis
Viechtbauer, W., & Cheung, M. W.-L. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.11 · Cited by 2,949
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
A Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,070
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D. K., Kubin, C., Barr, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012410 · Cited by 1,625
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2016638 · Cited by 1,318
Rosenberg, E. S., Dufort, E. M., Udo, T., Wilberschied, L. A., Kumar, J., Tesoriero, J., Weinberg, P., Kirkwood, J., Muse, A., DeHovitz, J., et al. (2020) · JAMA · doi:10.1001/jama.2020.8630 · Cited by 1,156
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Cavalcanti, A. B., Zampieri, F. G., Rosa, R. G., Azevedo, L. C. P., Veiga, V. C., Avezum, A., Damiani, L. P., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2019014 · Cited by 1,083
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038 · cited 1×
“did not have a standard of care comparative group [61,62].”
Factors associated with death in critically ill patients with coronavirus disease 2019 in the US
Gupta, S., Hayek, S. S., Wang, W., Chan, L., Mathews, K. S., Melamed, M. L., Brenner, S. K., Leonberg-Yoo, A., Schenck, E. J., Radbel, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3596 · Cited by 957
McAuley, L., Pham, B., Tugwell, P., & Moher, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02786-0 · Cited by 812
Mercuro, N. J., Yen, C. F., Shim, D. J., Maher, T. R., McCoy, C. M., Zimetbaum, P. J., & Gold, H. S. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1834 · Cited by 698
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 664
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19
Magagnoli, J., Narendran, S., Pereira, F., Cummings, T. H., Hardin, J. W., Sutton, S. S., & Ambati, J. (2020) · Med · doi:10.1016/j.medj.2020.06.001 · Cited by 656
Grey literature in meta-analyses of randomized trials of health care interventions
Hopewell, S., McDonald, S., Clarke, M. J., & Egger, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000010.pub3 · Cited by 598 · cited 1×
“There is limited evidence to identify whether grey studies have a poorer methodological quality than published studies [82].”
Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., et al. (2020) · BMJ · doi:10.1136/bmj.m1844 · Cited by 566
Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Wang, D. D., Huitsing, K., Brar, I., Alangaden, G. J., Ramesh, M. S., McKinnon, J. E., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.099 · Cited by 546
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial
Skipper, C. P., Pastick, K. A., Engen, N. W., Bangdiwala, A. S., Abassi, M., Lofgren, S. M., Williams, D. A., Okafor, E. C., Pullen, M. F., Nicol, M. R., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4207 · Cited by 539
Phase-adjusted estimation of the number of Coronavirus Disease 2019 cases in Wuhan, China
Wang, H., Wang, Z., Dong, Y., Chang, R., Xu, C., Yu, X., Zhang, S., Tsamlag, L., Shang, M., Huang, J., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-0148-0 · Cited by 496
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
Cravedi, P., Mothi, S. S., Azzi, Y., Haverly, M., Farouk, S. S., Pérez-Sáez, M. J., Redondo-Pachón, M. D., Murphy, B., Florman, S., Cyrino, L. G., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16185 · Cited by 390
Al-Bari, M. A. A. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.293 · Cited by 382
Bi-directional differentiation of single bronchioalveolar stem cells during lung repair
Liu, K., Tang, M., Liu, Q., Han, X., Jin, H., Zhu, H., Li, Y., He, L., Ji, H., & Zhou, B. (2020) · Cell Discovery · doi:10.1038/s41421-019-0132-8 · Cited by 360
Saleh, M., Gabriels, J., Chang, D., Soo Kim, B., Mansoor, A., Mahmood, E., Makker, P., Ismail, H., Goldner, B., Willner, J., et al. (2020) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.120.008662 · Cited by 340
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Maisonnasse, P., Guedj, J., Contreras, V., Behillil, S., Solas, C., Marlin, R., Naninck, T., Pizzorno, A., Lemaitre, J., Gonçalves, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2558-4 · Cited by 334
Andreani, J., Le Bideau, M., Duflot, I., Jardot, P., Rolland, C., Boxberger, M., Wurtz, N., Rolain, J.-M., Colson, P., La Scola, B., et al. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104228 · Cited by 319
Zhang, L.-K., Sun, Y., Zeng, H., Wang, Q., Jiang, X., Shang, W.-J., Wu, Y., Li, S., Zhang, Y.-L., Hao, Z.-N., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-00235-0 · Cited by 298
Chorin, E., Wadhwani, L., Magnani, S., Dai, M., Shulman, E., Nadeau-Routhier, C., Knotts, R., Bar-Cohen, R., Kogan, E., Barbhaiya, C., et al. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.05.014 · Cited by 295
Risk Factors for Mortality in Patients with COVID-19 in New York City
Mikami, T., Miyashita, H., Yamada, T., Harrington, M., Steinberg, D., Dunn, A., & Siau, E. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05983-z · Cited by 284
Bessière, F., Roccia, H., Delinière, A., Charrière, R., Chevalier, P., Argaud, L., & Cour, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1787 · Cited by 270
COVID-19 in patients with lung cancer
Luo, J., Rizvi, H., Preeshagul, I. R., Egger, J. V., Hoyos, D., Bandlamudi, C., McCarthy, C. G., Falcon, C. J., Schoenfeld, A. J., Arbour, K. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.007 · Cited by 267
Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., Alser, O., Alshammari, T. M., Biedermann, P., Banda, J. M., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30276-9 · Cited by 258
Lagier, J.-C., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A., Honoré, S., Gaubert, J.-Y., Fournier, P.-E., Tissot-Dupont, H., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101791 · Cited by 254
Alberici, F., Delbarba, E., Manenti, C., Econimo, L., Valerio, F., Pola, A., Maffei, C., Possenti, S., Lucca, B., Cortinovis, R., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.030 · Cited by 248
Horby, P., Mafham, M., Linsell, L., Bell, J. L., Staplin, N., Emberson, J. R., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., et al. (2020) · medRxiv · doi:10.1101/2020.07.15.20151852 · Cited by 233
Hernandez, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2496 · Cited by 222
Dyall, J., Gross, R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Hensley, L. E., Frieman, M. B., & Jahrling, P. B. (2017) · Drugs · doi:10.1007/s40265-017-0830-1 · Cited by 199
Sarma, P., Kaur, H., Kumar, H., Mahendru, D., Avti, P., Bhattacharyya, A., Prajapat, M., Shekhar, N., Kumar, S., Singh, R., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25898 · Cited by 191
The association between treatment with heparin and survival in patients with Covid-19
Ayerbe, L., Risco, C., & Ayis, S. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02162-z · Cited by 176
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study
Ip, A., Berry, D. A., Hansen, E., Goy, A. H., Pecora, A. L., Sinclaire, B., Bednarz, U., Marafelias, M., Berry, S. M., Berry, N., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237693 · Cited by 169
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19
Yu, B., Li, C., Chen, P., Zhou, N., Wang, L., Li, J., Jiang, H., & Wang, D.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1732-2 · Cited by 161
Alexander, P., Debono, V. B., Mammen, M., Iorio, A., Aryal, K., Deng, D., Brocard, E., & Alhazzani, W. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.04.016 · Cited by 144
Rivera, D. R. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., Lopes, G. D. L., Jr., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0941 · Cited by 137
“Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”
Singh, A. K., Singh, R., Singh, R., & Misra, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.05.017 · Cited by 135
Hydroxychloroquine prophylaxis for COVID-19 contacts in India
Rathi, S., Ish, P., Kalantri, A., & Kalantri, S. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30313-3 · Cited by 120
Huang, M., Li, M., Xiao, F., Pang, P., Liang, J., Tang, T., Liu, S., Chen, B., Shu, J., You, Y., et al. (2020) · National Science Review · doi:10.1093/nsr/nwaa113 · Cited by 117
Sánchez-Álvarez, J. E., Fontán, M. P., Martín, C. J., Pelícano, M. B., Cabezas-Reina, C. J., Sevillano, Á., Melilli, E., Crespo, M., Heras, M. M., & y Pino, M. D. D. P. (2020) · Nefrología · doi:10.1016/j.nefro.2020.04.002 · Cited by 114
Khamis, F. A., Al-Zakwani, I. S., Naamani, H. A., Lawati, S. A., Pandak, N., Omar, M. B., Bahrani, M. A., Bulushi, Z. A., Khalili, H. A., Salmi, I. A., et al. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.06.002 · Cited by 111
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin
Nguyen, L. S., Dolladille, C., Drici, M., Fenioux, C., Alexandre, J., Mira, J. P., Moslehi, J. J., Roden, D. M., Funck‐Brentano, C., & Salem, J. (2020) · Circulation · doi:10.1161/circulationaha.120.048238 · Cited by 109
Fontana, F., Alfano, G., Mori, G., Amurri, A., Tei, L., Ballestri, M., Leonelli, M., Facchini, F., Damiano, F., Magistroni, R., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15935 · Cited by 102
Review of trials currently testing treatment and prevention of COVID-19
Fragkou, P. C., Belhadi, D., Peiffer‐Smadja, N., Moschopoulos, C. D., Lescure, F.-X., Janocha, H., Karofylakis, E., Yazdanpanah, Y., Mentré, F., Skevaki, C. L., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.05.019 · Cited by 98
Self-citationMinimum costs to manufacture new treatments for COVID-19
Hill, A. M., Wang, J., Levi, J., Heath, K., & Fortunak, J. (2020) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30018-2 · Cited by 93
Rogado, J., Obispo, B., Pangua, C., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02381-z · Cited by 92
Mallat, J., Hamed, F., Balkis, M. M., Mohamed, M. A., Mooty, M., Malik, A., Nusair, A. R., & Bonilla, M.-F. (2020) · Medicine · doi:10.1097/md.0000000000023720 · Cited by 55
Bousquet, G., Falgarone, G., Deutsch, D., Derolez, S., Lopez‐Sublet, M., Goudot, F., Amari, K., Uzunhan, Y., Bouchaud, O., & Pamoukdjian, F. (2020) · Aging · doi:10.18632/aging.103583 · Cited by 51
Lecronier, M., Beurton, A., Burrel, S., Haudebourg, L., Déléris, R., Marec, J. L., Virolle, S., Nemlaghi, S., Bureau, C., Mora, P., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03117-9 · Cited by 50
Paccoud, O., Tubach, F., Baptiste, A., Bleibtreu, A., Hajage, D., Monsel, G., Tebano, G., Boutolleau, D., Klement-Frutos, E., Godefroy, N., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa791 · Cited by 39
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
Skipper, C. P., & Boulware, D. R. (2021) · Annals of Internal Medicine · doi:10.7326/l20-1426 · Cited by 37
Sánchez-Álvarez, J. E., Fontán, M. P., Martín, C. J., Blasco, M., Cabezas-Reina, C. J., Sevillano, Á., Melilli, E., Crespo, M., Heras, M. M., & y Pino, M. D. D. P. (2020) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2020.04.002 · Cited by 35
Sbidian, É., Josse, J., Lemaître, G., Meyer, I., Bernaux, M., Gramfort, A., Lapidus, N., Paris, N., Neuraz, A., Lerner, I., et al. (2020) · medRxiv · doi:10.1101/2020.06.16.20132597 · Cited by 33
Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non- human primatesPreprint
Maisonnasse, P., Guedj, J., Contreras, V., Behillil, S., Solas, C., Marlin, R., Naninck, T., Pizzorno, A., Lemaître, J., Gonçalves, A., et al. (2020) · doi:10.21203/rs.3.rs-27223/v1 · Cited by 29
Patel, T. K., Barvaliya, M. J., Kevadiya, B. D., Patel, P. B., & Bhalla, H. L. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09930-x · Cited by 28
Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19
Hernández, A. V., Roman, Y. M., Pasupuleti, V., Barboza, J. J., & White, C. M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1257 · Cited by 27
SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience
Fontana, F., Giaroni, F., Frisina, M., Alfano, G., Mori, G., Lucchi, L., Magistroni, R., & Cappelli, G. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa148 · Cited by 26
Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare SystemPreprint
Wang, A., Zhong, X., & Hurd, Y. L. (2020) · medRxiv · doi:10.1101/2020.06.11.20128926 · Cited by 25
Fontana, F., Giaroni, F., Frisina, M., Alfano, G., Mori, G., Lucchi, L., Magistroni, R., & Cappelli, G. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa084 · Cited by 23
Patel, T. K., Barvaliya, M. J., Kevadiya, B. D., Patel, P. B., & Bhalla, H. L. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09940-9 · Cited by 10
Cited by
Network medicine framework for identifying drug-repurposing opportunities for COVID-19
Morselli Gysi, D., do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025581118 · Cited by 107
“Note that a drug can have inhibitory effect in vitro that might not replicate in vivo, as observed for chloroquine and hydroxychloroquine (39).”
BackgroundCOVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective
Cavaillon, J.-M., & Osuchowski, M. F. (2021) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2021.04.003 · Cited by 17
Metadata
- Authors
- Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 27
- Issue
- 1
- Pages
- 19-27
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W3080857519
- Cited by
- 306
- References
- 78
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.